XOMA (US) LLC

XOMA Corporation is a biotechnology company focused on developing and commercializing therapeutic antibodies. While their website doesn't explicitly state "LLC," it's clear from their SEC filings and general presence that they operate as a publicly traded corporation. Their primary focus lies in developing novel antibody therapeutics targeting various diseases. Their pipeline includes both early and late-stage candidates. They utilize their proprietary antibody engineering technology platform to generate high-affinity, highly specific antibodies, aiming for improved efficacy and safety profiles compared to existing treatments. Their work spans several therapeutic areas, though specific details on current projects would require further research beyond the provided website. XOMA's history reflects a long-standing commitment to antibody research and development, with a track record of progressing molecules through various stages of clinical testing and commercialization, though the specific details of their past achievements are not directly apparent on their homepage. Their business model centers around the discovery, development, and potential licensing or commercialization of their antibody-based therapeutic candidates. In essence, XOMA Corporation is a biotechnology company dedicated to leveraging its antibody engineering expertise to address unmet medical needs.